Genesis Healthcare, Inc.

OTCPK:GENN Stock Report

Market Cap: US$177.0

Genesis Healthcare Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Genesis Healthcare's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Dec 2020

Recent past performance updates

Recent updates

Genesis: Debt Wall In 2022

Dec 08

Genesis Healthcare EPS beats by $0.21, misses on revenue

Nov 09

Revenue & Expenses Breakdown

How Genesis Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:GENN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 203,906-595950
30 Sep 204,123-635930
30 Jun 204,308466010
31 Mar 204,496636160
31 Dec 194,566155940
30 Sep 194,616-435130
30 Jun 194,710-1474290
31 Mar 194,837-1823360
31 Dec 184,977-2352790
30 Sep 185,119-2563420
30 Jun 185,217-5713540
31 Mar 185,286-5973980
31 Dec 175,374-5794060
30 Sep 175,423-4673590
30 Jun 175,501-1143610
31 Mar 175,568-723280
31 Dec 165,625-643320
30 Sep 165,657-3523320
30 Jun 165,656-3613340
31 Mar 165,645-3553340
31 Dec 155,519-4253260
30 Sep 155,278-2833160
30 Jun 155,056-2983020
31 Mar 154,842-3122880
31 Dec 144,690-2402790
30 Sep 144,641-1703920

Quality Earnings: Insufficient data to determine if GENN has high quality earnings.

Growing Profit Margin: Insufficient data to determine if GENN's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if GENN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare GENN's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if GENN's earnings growth over the past year exceeded the Healthcare industry average.


Return on Equity

High ROE: GENN has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/12 20:40
End of Day Share Price 2025/03/12 00:00
Earnings2020/12/31
Annual Earnings2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genesis Healthcare, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joanna Sylvia GajukBofA Global Research
Joseph FranceCantor Fitzgerald & Co.
Janice QuekCFRA Equity Research